Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies

[1] Ashbee HR(2014)Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology J Antimicrob Chemother 69 1162-1176

[2] Barnes RA(1985)Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France Therapie 40 111-118

[3] Johnson EM(2016)Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease J Antimicrob Chemother 71 718-726

[4] Bégaud B(2003)Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults Antimicrob Agents Chemother 47 2788-2795

[5] Evreux JC(2015)Superior serum concentrations with posaconazole delayed-release tablets compared to suspension formulation in hematological malignancies Antimicrob Agents Chemother 59 4424-4428

[6] Jouglard J(2016)Therapeutic drug monitoring of posaconazole: an update Curr Fungal Infect Rep 10 51-61

[7] Lagier G(2014)Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia Antimicrob Agents Chemother 58 5758-5765

[8] Cornely OA(2015)Retrospective comparison of posaconazole levels in patients taking the delayed-release tablet versus the oral suspension Antimicrob Agents Chemother 59 4914-4918

[9] Duarte RF(2010)Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma Clin Pharmacol Ther 88 115-119

[10] Haider S(2014)Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity Antimicrob Agents Chemother 58 6993-6995

[1] Ashbee HR(2014)Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology J Antimicrob Chemother 69 1162-1176

[2] Barnes RA(1985)Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France Therapie 40 111-118

[3] Johnson EM(2016)Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease J Antimicrob Chemother 71 718-726

[4] Bégaud B(2003)Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults Antimicrob Agents Chemother 47 2788-2795

[5] Evreux JC(2015)Superior serum concentrations with posaconazole delayed-release tablets compared to suspension formulation in hematological malignancies Antimicrob Agents Chemother 59 4424-4428

[6] Jouglard J(2016)Therapeutic drug monitoring of posaconazole: an update Curr Fungal Infect Rep 10 51-61

[7] Lagier G(2014)Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia Antimicrob Agents Chemother 58 5758-5765

[8] Cornely OA(2015)Retrospective comparison of posaconazole levels in patients taking the delayed-release tablet versus the oral suspension Antimicrob Agents Chemother 59 4914-4918

[9] Duarte RF(2010)Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma Clin Pharmacol Ther 88 115-119

[10] Haider S(2014)Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity Antimicrob Agents Chemother 58 6993-6995